Characteristics of nanobacteria and their possible role in stone formation

Urological Research

Volumn 31, Issue 2, 2003, Pages 47-54

  Kajander, E Olavi ^a,b   Ciftcioglu, Neva ^c   Aho, Katja ^a   Garcia Cuerpo, Enrique ^d  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b Nanobac Oy   (Finland)

^c NASA JOHNSON SPACE CENTER   (United States)

^d UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Calcification; Kidney stones; Nanobacteria; Nephrocalcinosis; Nephrolithiasis

Indexed keywords

CALCIUM OXALATE; CALCIUM PHOSPHATE; URATE; URIC ACID;

BACTERIAL INFECTION; BACTERIUM; CRYSTALLIZATION; HUMAN; HYPOTHESIS; KIDNEY COLLECTING TUBULE; NANOBACTERIUM; NEPHROLITHIASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; STONE FORMATION; UROTHELIUM;

EID: 0038339531     PISSN: 03005623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00240-003-0304-7     Document Type: Review

References (52)

1. Aho K (2002) In vivo biodistribution and toxicity of nanobacteria in rodents. In: International Nanobacteria Minisymposium, March 8 2001, Kuopio. Book of abstracts, Kuopio University Press, Kuopio, (in press). Abstract at http://www.nanobac.com/nbminisymp080301/page9.html
2. Aho K, Kajander EO, Ciftcioglu N, Hjelle JT, Miller-Hjelle MA (2002) Screening of human gamma globulin products for nanobacteria markers. American Society for Microbiology, 102nd General Meeting; May 19-23 2002, Salt Lake City. Abstract Y-10, p. 507.
3. Akerman KK, Kuikka JT, Ciftcioglu N, Parkkinen J, Bergstrom KA, Kuronen I, Kajander EO (1997) Radiolabeling and in vivo distribution of nanobacteria in rabbit. Proc SPIE Int Soc Opt Eng 3111:436
4. Bjorklund M, Ciftcioglu N, Kajander EO (1998) Extraordinary survival of nanobacteria under extreme conditions. Proc SPIE Int Soc Opt Eng 3441:123
5. Bone HG3rd, Zerwekh JE, Britton F, Pak CY (1979) Treatment of calcium urolithiasis with diphosphonate: efficacy and hazards. J Urol 121:568
6. Burton SK (2001) Nanobacteria growth characteristics and biofilm formation. Proceedings American Society of Microbiology 101st General Meeting, May 20-24, 2001, Orlando. Abstract I-98, p 437
7. Carr RJ (1954) A new theory of the formation of renal calculi. Brit J Urol 26:105
8. Ciftcioglu N, Kajander EO (1998) Interaction of nanobacteria with cultured mammalian cells. Pathophysiology 4:259
9. Ciftcioglu N, Kajander EO (2000) Growth factors for nanobacteria. Proc SPIE Int Soc Opt Eng 3755:113
10. Ciftcioglu N, Pelttari A, Kajander EO (1997) Extraordinary growth phases of nanobacteria isolated from mammalian blood. Proc SPIE Int Soc Opt Eng 3111:429
11. Ciftcioglu N, Bjorklund M, Kajander EO (1998) Stone formation and calcification by nanobacteria in human body. Proc SPIE Int Soc Opt Eng 3441:105
12. Ciftcioglu N, Ciftcioglu V, Vali H, Turcott E, Kajander EO (1998) Sedimentary rocks in our mouth: dental pulp stones made by nanobacteria. Proc SPIE Int Soc Opt Eng 3441:130
13. Ciftcioglu N, Bjorklund M, Kuorikoski K, Bergstrom K, Kajander EO (1999) Nanobacteria: an infectious cause for kidney stone formation. Kidney Int 56:1893
14. Ciftcioglu N, Miller-Hjelle MA, Hjelle JT, Kajander EO (2002) Inhibition of nanobacteria by antimicrobial drugs as measured by a modified microdilution method. Antimicrob Agents Chemother 46:2077
15. Cisar JO, Xu D-Q, Thompson J, Swaim W, Hu L, Kopecko DJ (2000) An alternative interpretation of nanobacteria-induced biomineralization. Proc Natl Acad Sci U S A 97:11511
16. Fan J, Chandhoke PS (1999) Examination of crystalluria in freshly voided urines of recurrent calcium stone formers and normal individuals using a new filter technique. J Urol 161:1685
17. Folk RL (1993) SEM imaging of bacteria and nannobacteria in carbonate sediments and rocks. J Sediment Petrol 63:990
18. Garcia Cuerpo E, Kajander EO, Ciftcioglu N, Lovaco Castellano F, Correa C, Gonzalez J, Mampaso F, Liano F, Garcia de Gabiola E, Escudero Barrileiro A (2000): Nanobacteria. Un modelo de neo-litogenesis experimental. Arch Esp Urol 53:291
19. Hjelle JT, Miller-Hjelle MA, Poxton IR, Kajander EO, Ciftcioglu N, Jones ML, Caughey RC, Brown R, Millikin PD, Darras FS (2000) Endotoxin and nanobacteria in polycystic kidney disease. Kidney Int 57:2360
20. Hojgaard I, Fornander AM, Nilsson MA, Tiselius HG (1999) Crystallization during volume reduction of solutions with a composition corresponding to that in the collecting duct: the influence of hydroxyapatite seed crystals and urinary macromolecules. Urol Res 27:417
21. Holmberg M (2002) Serological evidence for nanobacteria prevalence suggests a possible zoonosis. In: International Nanobacteria Minisymposium, March 8 2001, Kuopio. Book of abstracts, Kuopio University Press, Kuopio, (in press). Abstract at http://www.nanobac.com/nbminisymp080301/page10.html
22. Kajander EO, Ciftcioglu N (1998) Nanobacteria: an alternative mechanism for pathogenic intra- and extracellular calcification and stone formation. Proc Natl Acad Sci U S A 95:8274
23. Kajander EO, Ciftcioglu N (2000) Nanobacteria as extremophiles. Proc SPIE Int Soc Opt Eng 3755:106
24. Kajander EO, Kuronen I, Akerman K, Pelttari A, Ciftcioglu N (1997) Nanobacteria from blood, the smallest culturable autonomously replicating agent on Earth. Proc SPIE Int Soc Opt Eng 3111:420
25. Kajander EO, Bjorklund M, Ciftcioglu N (1998) Mineralization by nanobacteria. Proc SPIE Int Soc Opt Eng 3441:86
26. Kajander EO, Heinonen T, Kuronen I, Luoto K, Ciftcioglu N (1999) Nanobacteria, mycoplasma and bacterial L-forms; problems for sterile filtration. In: Wirtanen G, Salo S, Mikkola A (eds) 30th R3-Nordic Contamination Control Symposium, Helsinki, Finland, May 30-June 2, 1999. VTT Technical Research Centre of Finland, Espoo, p 279
27. Kajander EO, Ciftcioglu N, Aho K (2001) Detection of nanobacteria in viral vaccines. Proceedings of the American Society of Microbiology, 101st General Meeting, 20-24 May 2001, Orlando. Abstract Y-3, p 736.
28. Kajander EO, Ciftcioglu N, Miller-Hjelle MA, Hjelle JT (2001) Nanobacteria: controversial pathogens in nephrolithiasis and polycystic kidney disease. Curr Opin Neprol Hypertens 10:445
29. Lieske JC, Toback FG (2000) Renal cell-urinary crystal interactions. Curr Opin Neprol Hypertens 9:349
30. Low RK, Stoller ML, Schreiber CK (2000) Metabolic and urinary risk factors associated with Randall's papillary plaques. J Endourol 14:507
31. Martini LA, Wood RJ (2000) Should dietary calcium and protein be restricted in patients with nephrolithiasis? Nutr Rev 58:111
32. McKay DS, Gibson EKJr, Thomas-Keprta KL, Vali H, Romanek CS, Clemett SJ, Chillier XD, Maechling CR, Zare RN (1996) Search for past life on Mars: Possible relic biogenic activity in Martian meteorite ALH840001. Science 273:924
33. Miller-Hjelle MA, Hjelle JT, Ciftcioglu N, Kajander EO (2003). Nanobacteria: methods for growth and identification of this recently discovered calciferous microbe. In: Olson W (ed) Rapid analytical microbiology: the chemistry and physics of microbial identification. Sue Horwood, Storrington (in press)
34. Price PA, Buckley JR, Williamson MK (2001) The amino bisphosphonate ibandronate prevents vitamin D toxicity and inhibits vitamin D-induced calcification of arteries, cartilage, lungs and kidneys in rats. J Nutr 131:2910
35. Price PA, Faus SA, Williamson MK (2001) Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 21:817
36. Price PA, Thomas GR, Pardini AW, Figueira WF, Caputo JM, Williamson MK (2002) Discovery of a high molecular weight complex of calcium, phosphate, fetuin, and matrix γ-carboxyglutamic acid protein in the serum of etidronate-treated rats. J Biol Chem 277:3926
37. Price PA, Omid N, Than TN, Williamson MK (2002) The amino bisphosphonate ibandronate prevents calciphylaxis in the rat at doses that inhibit bone resorption. Calcif Tissue Int 71:356
38. Puskás L (2002) Detection of nanobacteria in human atherosclerotic plaques. In: International Nanobacteria Minisymposium, March 8 2001, Kuopio. Book of abstracts, Kuopio University Press, Kuopio, (in press). Abstract at http:// www.nanobac.com/nbminisymp080301/page13.html
39. Ramello A, Vitale C, Marangella M (2000) Epidemiology of nephrolithiasis. J Nephrol 13:S45
40. Randall A (1937) The origin and growth of renal calculi. Ann Surg 105:1009
41. Scheinmann SJ (1999) Nephrolithiasis. Semin Nephrol 19:381
42. Schwartz BF, Bruce J, Leslie S, Stoller ML (2001) Rethinking the role of urinary magnesium in calcium urolithiasis. J Endourol 15:233
43. Sidhu H, Schmidt ME, Cornelius JG, Thamilselvan S, Khan SR, Hesse A, Peck AB (1999) Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract-dwelling bacterium Oxalobacter formigenes: possible prevention by gut recolonization or enzyme replacement therapy. J Am Soc Nephrol 10 (Suppl 14):S334
44. Sommer AP, Pinheiro AL, Mester AR, Franke RP, Whelan HT (2001) Biostimulatory windows in low-intensity laser activation: lasers, scanners and NASA's light-emitting diode array system. J Clin Laser Med Surg 19:29
45. Sommer AP, Hassinen HI, Kajander EO (2002) Light induced replication of nanobacteria-a preliminary report. J Clin Laser Med Surg 20:241
46. Sommer AP, Oron U, Kajander EO, Mester AR (2002) Stressed cells survive better with light. J Proteome Res 1:475
47. Söhnel O, Grases F (1993) Fine structure of calcium oxalate monohydrate renal calculi. Nephron 63:176
48. Uwins PJR, Webb RI, Taylor AP (1998) Novel nano-organisms from Australian sandstones. Am Minerol 83:1541
49. Vali H, McKee MD, Ciftcioglu N, Sears SK, Plows FL, Chevet E, Ghiasi P, Plavsic M, Kajander EO, Zare RN (2001) Nano-forms: a new type of protein-associated mineralization. Geochim Cosmochim Acta 65:63
50. Wahl C, Hess B (2000) Kidney calculi - is nutrition a trigger or treatment? Ther Umsch 57:138
51. Wainwright M (1999) Nanobacteria and associated 'elementary bodies' in human disease and cancer. Microbiology 145:2623
52. Ylitalo R (2002) Bisphosphonates and atherosclerosis. Gen Pharmacol 35:287